|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sponsorship and congruity theory: a theoretical framework for explaining consumer attitude and recall of event sponsorship 显示文摘 | Emma Jagre John J Watson and John G Watson | 2001 | Advance in Consumer Research2001，28，： | 1 |
| 2 | Sponsorship and congruity theory:a theoretical framework for explaining consumer attitude and recall of event sponsorship显示文摘 | Emma Jagre John J Watson | 2001 | Advance in Consumer Research2001，，28： | 1 |
| 3 | Development of a modular, biocompatible thiolated gelatin microparticle platform for drug delivery and tissue engineering applications显示文摘The field of biomaterials has advanced significantly in the past decade.With the growing need for high-throughput manufacturing and screening,the need for modular materials that enable streamlined fabrication and analysis of tissue engineering and drug delivery schema has emerged.Microparticles are a powerful platform that have demonstrated promise in enabling these technologies without the need to modify a bulk scaffold.This building block paradigm of using microparticles within larger scaffolds to control cell ratios,growth factors and drug release holds promise.Gelatin microparticles(GMPs)are a well-established platform for cell,drug and growth factor delivery.One of the challenges in using GMPs though is the limited ability to modify the gelatin post-fabrication.In the present work,we hypothesized that by thiolating gelatin before microparticle formation,a versatile platform would be created that preserves the cytocompatibility of gelatin,while enabling post-fabrication modification.The thiols were not found to significantly impact the physicochemical properties of the microparticles.Moreover,the thiolated GMPs were demonstrated to be a biocompatible and robust platform for mesenchymal stem cell attachment.Additionally,the thiolated particles were able to be covalently modified with a maleimide-bearing fluorescent dye and a peptide,demonstrating their promise as a modular platform for tissue engineering and drug delivery applications. | Hannah A.Pearce Yu Seon Kim Emma Watson Kiana Bahrami Mollie M.Smoak Emily Y.Jiang Michael Elder Tate Shannon Antonios G.Mikos | 2021 | Regenerative Biomaterials2021，8，3： | 1 |
| 4 | 艾玛·沃特森就性别平等在联合国的演讲显示文摘你对艾玛·沃特森的了解可能还停留在她塑造的一系列经典的人物形象上,但你一定不知道她还是拥护人道主义的坚定女性,致力于性别平等和女性赋权工作。本文是担任“联合国妇女亲善大使”的艾玛·沃特森在出席促进性别平等活动“He For She”时所发表的精彩演讲。她在演讲中反对性别歧视,呼吁男女平等。 | Emma Watson 魏建国 | 2015 | 英语沙龙(原版阅读)2015，，3： | 1 |
| 5 | 可逃生渔网显示文摘英国设计师Dan Watson重新设计的拖网Safety Net获得了2012年度James Dyson设计奖。这款被重新设计的在拖网捕鱼中使用的普通渔网上增加了一些特定大小的圆环,这些圆环内嵌有LED灯,能在水里发出淡淡的光,方便小鱼穿过这些圆环逃生,以保证生态圈的平衡可持续发展。 | Emma Dan Watson | 2013 | 设计2013，26，3： | 0 |
| 6 | 英国国家医疗服务体系实施医患共同决策显示文摘格林·埃尔温(Glyn Elwyn)和他同事认为,在让患者选择他们的治疗方案之前,首先应创建一个可以为医生和患者提供信息的工具平台。在美国、加拿大和英国,促进医患共同决策的政策正日益受到关注1-3。究其原因,一部分是认识到让患者适当参与自己的医疗决策是极其重要的伦理要求45,一部分是为了积累能够证明治疗对患者有益的证据。共同决策是临床医生和患者利用现有的最可靠证据共同做出临床决定的一种方法。医生鼓励患者考虑现有的筛查、治疗或管理方案,权衡每种方案可能的利弊,这样他们才能表达出自己的喜好,有助于为自己做出最佳选择。共同决策既体现了对患者自主性的尊重,也推动了患者积极参与临床诊疗。 | 梁立智(译) Glyn Elwyn Steve Laitner Angela Coulter Emma Walker Paul Watson Richard Thomson | 2014 | 英国医学杂志中文版2014，17，S01： | 0 |
| 7 | Corrigendum to “Advances in In Vitro and In Vivo Bioreactor-Based Bone Generation for Craniofacial Tissue Engineering”显示文摘In the review article“Advances in In Vitro and In Vivo Bioreactor-Based Bone Generation for Craniofacial Tissue Engineering,”the authors made an error in Table.In Table,10 cells in the Results column contain the word“enter,”which was erroneously added instead of starting a new line of text during proofing.This error did not affect the results,discussion,or conclusion of this paper.Table 1 has now been corrected in the PDF and HTML(full text). | Emma Watson Antonios G.Mikos | 2023 | Biomedical Engineering Frontiers2023，4，1： | 0 |
| 8 | Advances in In Vitro and In Vivo Bioreactor-Based Bone Generation for Craniofacial Tissue Engineering显示文摘Craniofacial reconstruction requires robust bone of specified geometry for the repair to be both functional and aesthetic.While native bone from elsewhere in the body can be harvested,shaped,and implanted within a defect,using either an in vitro or in vivo bioreactors eliminates donor site morbidity while increasing the customizability of the generated tissue.In vitro bioreactors utilize cells harvested from the patient,a scaffold,and a device to increase mass transfer of nutrients,oxygen,and waste,allowing for generation of larger viable tissues.In vivo bioreactors utilize the patient’s own body as a source of cells and of nutrient transfer and involve the implantation of a scaffold with or without growth factors adjacent to vasculature,followed by the eventual transfer of vascularized,mineralized tissue to the defect site.Several different models of in vitro bioreactors exist,and several different implantation sites have been successfully utilized for in vivo tissue generation and defect repair in humans.In this review,we discuss the specifics of each bioreactor strategy,as well as the advantages and disadvantages of each and the future directions for the engineering of bony tissues for craniofacial defect repair. | Emma Watson Antonios G.Mikos | 2023 | Biomedical Engineering Frontiers2023，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员